Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 301 AL 315

The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials

Olsson B, Schott JM, Blennow K, Zetterberg H.

Expert Rev Neurother. 2017 Aug;17(8):767-775. doi: 10.1080/14737175.2017.1341311. Epub 2017 Jun 19.

Characterizing Alzheimer's disease through metabolomics and investigating anti-Alzheimer's disease effects of natural products

Yi L, Liu W, Wang Z, Ren D, Peng W.

Ann N Y Acad Sci. 2017 Jun;1398(1):130-141. doi: 10.1111/nyas.13385. Epub 2017 Jun 20.

[Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients]

Asai M, Kawakubo T, Mori R, Iwata N.

Yakugaku Zasshi. 2017;137(7):801-805. doi: 10.1248/yakushi.16-00236-2.

Potential Roles of Exosomal MicroRNAs as Diagnostic Biomarkers and Therapeutic Application in Alzheimer's Disease

Chen JJ, Zhao B, Zhao J, Li S.

Neural Plast. 2017;2017:7027380. doi: 10.1155/2017/7027380. Epub 2017 Jul 9.

[Alzheimer's disease from Auguste Deter to the present : Progress, disappointments and open questions]

Pantel J.

Z Gerontol Geriatr. 2017 Oct;50(7):576-587. doi: 10.1007/s00391-017-1307-2. Epub 2017 Sep 18.

Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome

Caraci F, Iulita MF, Pentz R, Flores Aguilar L, Orciani C, Barone C, Romano C, Drago F, Cuello AC.

Eur J Pharmacol. 2017 Dec 15;817:7-19. doi: 10.1016/j.ejphar.2017.10.004. Epub 2017 Oct 5.

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease

Ritchie CW, Russ TC, Banerjee S, Barber B, Boaden A, Fox NC, Holmes C, Isaacs JD, Leroi I, Lovestone S, Norton M, O'Brien J, Pearson J, Perry R, Pickett J, Waldman AD, Wong WL, Rossor MN, Burns A.

Alzheimers Res Ther. 2017 Oct 26;9(1):85. doi: 10.1186/s13195-017-0312-4.

Recent Progress in the Pharmacotherapy of Alzheimer's Disease

Khoury R, Patel K, Gold J, Hinds S, Grossberg GT.

Drugs Aging. 2017 Nov;34(11):811-820. doi: 10.1007/s40266-017-0499-x.

18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

Martínez G, Vernooij RW, Fuentes Padilla P, Zamora J, Flicker L, Bonfill Cosp X.

Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884.

The Role of Chromatography in Alzheimer's Disease Drug Discovery

Fiori J, De Simone A, Naldi M, Andrisano V.

Adv Chromatogr. 2017;53:75-107.

Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease

Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipic S, Agbaba D, Esteban G, Unzeta M, Nikolic K, Butini S, Marco-Contelles J.

Prog Neurobiol. 2017 Apr;151:4-34. doi: 10.1016/j.pneurobio.2015.12.003. Epub 2016 Jan 18.

Mirtazapine does not improve sleep disorders in Alzheimer's disease: results from a double-blind, placebo-controlled pilot study

Scoralick FM, Louzada LL, Quintas JL, Naves JO, Camargos EF, Nóbrega OT.

Psychogeriatrics. 2017 Mar;17(2):89-96. doi: 10.1111/psyg.12191. Epub 2016 Jan 27.

Resveratrol and Alzheimer's Disease: Mechanistic Insights

Ahmed T, Javed S, Javed S, Tariq A, Šamec D, Tejada S, Nabavi SF, Braidy N, Nabavi SM.

Mol Neurobiol. 2017 May;54(4):2622-2635. doi: 10.1007/s12035-016-9839-9. Epub 2016 Mar 19.

Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies

Amanatkar HR, Papagiannopoulos B, Grossberg GT.

Expert Rev Neurother. 2017 Jan;17(1):7-16. doi: 10.1080/14737175.2016.1194203. Epub 2016 Jun 9.

Autophagy and Alzheimer's Disease

Li Q, Liu Y, Sun M.

Cell Mol Neurobiol. 2017 Apr;37(3):377-388. doi: 10.1007/s10571-016-0386-8. Epub 2016 Jun 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias